Abraham Morgentaler, MD, shares why the recent publication of five studies on testosterone therapy in JAMA and JAMA Internal Medicine "was arguably the most important week ever for the science of testosterone therapy and its impact on men's health."
All treatments entail some risk, including T therapy. At this point, there are no compelling data to support the notion that T therapy is associated with CV risks, and there is suggestive evidence it may even be helpful.
Just a few years ago, it would have been unthinkable to offer testosterone therapy (TTh) to men with a history of prostate cancer. Yet several changes have occurred to make TTh a reasonable treatment option in men who are symptomatic from testosterone deficiency.